These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 26453294)

  • 1. Update on Mucin-1 immunotherapy in cancer: a clinical perspective.
    Rivalland G; Loveland B; Mitchell P
    Expert Opin Biol Ther; 2015; 15(12):1773-87. PubMed ID: 26453294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC1 immunotherapy.
    Beatson RE; Taylor-Papadimitriou J; Burchell JM
    Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
    Acres B; Lacoste G; Limacher JM
    Curr Top Microbiol Immunol; 2017; 405():79-97. PubMed ID: 25702159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
    Amedei A; Niccolai E; Prisco D
    Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.
    Guo M; You C; Dou J
    Biomed Pharmacother; 2018 Nov; 107():1318-1325. PubMed ID: 30257347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1 antibody-based therapeutics: the promise of cancer immunotherapy.
    Pourjafar M; Samadi P; Saidijam M
    Immunotherapy; 2020 Dec; 12(17):1269-1286. PubMed ID: 33019839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1 immunotherapy is here to stay.
    Kimura T; Finn OJ
    Expert Opin Biol Ther; 2013 Jan; 13(1):35-49. PubMed ID: 22998452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Making the most of mucin: a novel target for tumor immunotherapy.
    Barratt-Boyes SM
    Cancer Immunol Immunother; 1996 Nov; 43(3):142-51. PubMed ID: 9001567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances of MUC1 as a target for breast cancer immunotherapy.
    Yang E; Hu XF; Xing PX
    Histol Histopathol; 2007 Aug; 22(8):905-22. PubMed ID: 17503348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
    Hall RD; Gray JE; Chiappori AA
    Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC1 as a target antigen for cancer immunotherapy.
    Acres B; Limacher JM
    Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the immune system to treat lung cancer: rationale and clinical experience.
    Guibert N; Delaunay M; Mazières J
    Ther Adv Respir Dis; 2015 Jun; 9(3):105-20. PubMed ID: 25827132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospect and progress of personalized peptide vaccinations for advanced cancers.
    Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
    Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies used for MUC1 immunotherapy: preclinical studies.
    Tang CK; Apostolopoulos V
    Expert Rev Vaccines; 2008 Sep; 7(7):951-62. PubMed ID: 18767945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy: new insights].
    Geissler M; Weth R
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in strategies and methodologies in cancer immunotherapy.
    Lam SS; Zhou F; Hode T; Nordquist RE; Alleruzzo L; Raker J; Chen WR
    Discov Med; 2015 Apr; 19(105):293-301. PubMed ID: 25977192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.